HUMIRA

Type: Product
Name: HUMIRA
First reported Apr 22 2014 - Updated 16 hours ago - 1 reports

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

Researchmoz presents this most up-to-date research on" ". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.During the forecast period from 20122022, the ... [Published MyNewsDesk - Apr 22 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

The Prescription Drug Epidemic

A new report published Sunday by Natural Society says Americans consume 50% of the world's prescription drugs . That's a mind-blowing number, considering that Americans only make up 5 percent of the world population. This is the astonishing claim made ... [Published Examiner.com - Apr 21 2014]
First reported Apr 20 2014 - Updated Apr 21 2014 - 2 reports

Composing only 5% of the world population, Americans take 50% of all pharmaceutical drugs

© Natural SocietyWhile Americans comprise only 5 percent of the world population, we consume an incredible 50 percent of Big Pharma's drugs, as explained in Jeff Hays' documentary film, Doctored . Make no mistake. These drugs are meant to keep us imprisoned ... [Published Sott.net - Apr 21 2014]
First reported Apr 20 2014 - Updated Apr 20 2014 - 1 reports

Middle school girl from Longmont lobbies for psoriasis funding

For the Times-CallTwo syringes chill in the family's Longmont refrigerator along with the milk, eggs, meat and produce."It's like this little pot of gold I have in my fridge here. Two shots cost $3,200," Shayla Knight said of the clear package holding ... [Published Longmont Daily Times-Call - Apr 20 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

AbbVie moving some workers off Abbott campus

_ Fifteen months after splitting off from Abbott Laboratories, AbbVie Inc. is taking its first steps off its former parent’s sprawling north suburban campus.The North Chicago-based pharmaceutical firm told employees Friday that it will move up to 2,000 ... [Published Chicago Tribune - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 18 2014 - 1 reports

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights Celgene ... [Published Motley Fool Discussion Boards - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Do these 4 drug ads tell the truth?

Moody? Achy? Got high cholesterol? Watch TV and you’re apt to see a commercial pitching just the drug to cure what ails you—albeit with a long list of side effects. Drug companies, which spent some $3 billion in 2013 on ads, say that they educate consumers. ... [Published Consumer Reports - Apr 17 2014]
Entities: Drugs, Crestor, HUMIRA, Cymbalta
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Epirus concludes USD36m Series B financing

Biopharmaceutical company Epirus Biopharmaceuticals reported on Wednesday the completion of a USD36m Series B financing round led by Livzon Mabpharm and other investors. In conjunction with the financing, Daotian Fu PhD, the CEO of Livzon Mabpharm, was ... [Published Individual.com - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Boehringer lines up biosimilars of major drugs

Boehringer Ingelheim plans to make biosimilar versions of the drugs Humira, Avastin and MabThera/Rituxan as part of its ambitions in biopharmaceuticals.Speaking to journalists at the company's annual conference in Germany, chairman Andreas Barner confirmed ... [Published PMLive - Apr 17 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

AbbVie partners with Arabio for production in Saudi Arabia

Drugmaker joins Pfizer, Merck and others in the regionShareToolsAbbVie will partner with Arabio to manufacture Humira and other drugs in Saudi Arabia.--Courtesy of AbbVieAs growth has slowed in some emerging markets, Western drugmakers are looking to ... [Published FiercePharmaManufacturing - Apr 10 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 5 reports

The world’s 10 best-selling prescription drugs

Yearly sales of the injectable drug Humira an anti-inflammatory used to treat rheumatoid arthritis, psoriasis and Crohn’s disease have almost doubled over the past four years, to $ 10.7bn last year, making it the world’s top-selling drug for the second ... [Published FFOG.Net - Mar 28 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 2 reports

Can AbbVie's Legacy Products Deliver Further Growth?

Levothyroxine, the active ingredient in the hypothyroidism drug Synthroid, degrades quickly with exposure to light, moisture, oxygen, and carbohydrate excipients. Consequently, manufacturing complexities combined with a very narrow dosing range makes ... [Published Motley Fool - Mar 27 2014]

Quotes

"Psoriasis is a long-term disease with no cure that can have a significant impact on patients" said Steven Romano, global medicines development lead at Pfizer
"Sadly, Americans are more familiar with names like Abilify, Nexium, Humira, Plavix, Crestor, Advair Diskus, Enbrel, and Cymbalta, the top selling drugs of Big Pharma, than names like Aloe barbadensis, Curcuma longa, Allium sativum, Moringa oleifera, Vitis vinifera L, all indigenous plants that have healed millions around the world" the report says
"We're on a good path, with more information and more detail," he said. "I think this kind of data can be very helpful, but I don't think the first set is very (helpful)."
"It's like this little pot of gold I have in my fridge here. Two shots cost $3,200" Shayla Knight said of the clear package holding the double dose of an immune suppressing drug called Humira

More Content

All (220) | News (204) | Reports (0) | Blogs (16) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Earnings Roundup: What You Need to Know About G... [Published Motley Fool - 6 hours ago]
Market Update (NYSE:ABBV): AbbVie to Present Da... [Published Jutia Group - 8 hours ago]
House Calls: Managing rheumatoid arthritis [Published Paris Express - 9 hours ago]
Companies Betting on the Next 10 Blockbuster Drugs [Published 24/7 Wall St - 10 hours ago]
Pfizer set to file Xeljanz for psoriasis [Published PMLive - 12 hours ago]
Earnings Roundup: Baxter International Grows Ah... [Published Motley Fool - Apr 22 2014]
Market Report, "Prochymal (Crohn's Disease) - F... [Published SBWire - Apr 22 2014]
Dermatological Drugs Market Forecast 2014-2024 [Published Individual.com - Apr 22 2014]
PharmaPoint: Ulcerative Colitis - Global Drug F... [Published MyNewsDesk - Apr 22 2014]
The Prescription Drug Epidemic [Published Examiner.com - Apr 21 2014]
14 area doctors split $11M from Medicare [Published Worcester Telegram & Gazette - Apr 21 2014]
Composing only 5% of the world population, Amer... [Published Sott.net - Apr 21 2014]
Earnings Roundup: Look Beyond Abbott Labs' Shor... [Published Motley Fool - Apr 20 2014]
Composing Only 5% of the World Population, Amer... [Published PrisonPlanet - Apr 20 2014]
China Biotech In Review: Unnamed Entity Raises ... [Published Seeking Alpha - Apr 20 2014]
Middle school girl from Longmont lobbies for ps... [Published Longmont Daily Times-Call - Apr 20 2014]
What’s keeping the generic version of biologic ... [Published PBS - Apr 19 2014]
AbbVie moving some workers off Abbott campus [Published Chicago Tribune - Apr 18 2014]
Xenoport's Path Is Long, But The Potential Is T... [Published Seeking Alpha - Apr 18 2014]
Earnings Roundup: Johnson & Johnson Results Are... [Published Motley Fool - Apr 17 2014]
Earnings Primer: What's on Deck for Celgene, Ab... [Published Motley Fool Discussion Boards - Apr 17 2014]
AbbVie Candidate in Pivotal Study - Analyst Blog [Published Nasdaq - Apr 17 2014]
Why Zalicus Was Up Yesterday And Is Down Today [Published Bidness Etc - Apr 17 2014]
Do these 4 drug ads tell the truth? [Published Consumer Reports - Apr 17 2014]
AbbVie Candidate in Pivotal Study [Published Zacks.com - Apr 17 2014]
Epirus concludes USD36m Series B financing [Published Individual.com - Apr 17 2014]
Boehringer lines up biosimilars of major drugs [Published PMLive - Apr 17 2014]
Venture capital-backed Epirus raises $36m, merg... [Published AltAssets.net - Apr 17 2014]
Epirus to acquire Zalicus, creating a publicly-... [Published Pharma Letter - Apr 17 2014]
Novel therapy effective for plaque psoriasis [Published The Clinical Advisor - Apr 17 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Epirus grabs $36 mln Series B funds and merges ... [Published PE Hub Blog - Apr 16 2014]
Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that include Adage Capital, Greenwoods Investment, Gibralt US, Monashee Capital Partners, ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
A day late - AbbVie drops legal action in EU dr... [Published PharmaGossip - Apr 03 2014]
LONDON, April 3 (Reuters) - AbbVie, one of the two U.S. companies trying to stop Europe's drugs regulator from releasing previously secret clinical trials data, said on Thursday it had withdrawn lawsuits against the watchdog.The decision follows a move ...
CRMO "Chronic Recurrent Multifocal Osteomyelitis" [Published HealthBoards - Apr 01 2014]
Our 11 year old daughter was diagnosed with CRMO this past October. It started out in her knees and has spread to new places. She's been on Methotrexate since last year and started Enbrel injections in February with no luck. She just started the Humira ...
AbbVie Initiates New Clinical Trial to Evaluate... [Published PR Newswire: Health - Mar 20 2014]
NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.